Michael D. Winther
Singapore, Singapore
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Improving prescribing: a feasibility study of pharmacogenetic testing with clinical decision support in primary healthcare in Singapore.
Journal: Family practice
Published: November 23, 2022
CYP2C19 phenotype in South-East Asian Acute Coronary Syndrome patients and impact on major adverse cardiovascular events.
Journal: Journal of clinical pharmacy and therapeutics
Published: June 02, 2019
Southeast Asian Pharmacogenomics Research Network (SEAPharm): Current Status and Perspectives.
Journal: Public health genomics
Published: February 01, 2019
In search of a genetic explanation for LDLc variability in an FH family: common SNPs and a rare mutation in MTTP explain only part of LDL variability in an FH family.
Journal: Journal of lipid research
Published: December 28, 2018
Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults.
Journal: The pharmacogenomics journal
Published: August 29, 2017
Pharmacogenomics in Asia: a systematic review on current trends and novel discoveries.
Journal: Pharmacogenomics
Published: June 09, 2017
Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study.
Journal: British journal of clinical pharmacology
Published: May 26, 2016
Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors.
Journal: Bioorganic & medicinal chemistry
Published: October 30, 2014
Identification of four novel genes contributing to familial elevated plasma HDL cholesterol in humans.
Journal: Journal of lipid research
Published: March 11, 2014
Opportunities and challenges in developing stearoyl-coenzyme A desaturase-1 inhibitors as novel therapeutics for human disease.
Journal: Journal of medicinal chemistry
Published: December 04, 2013
Systematic evaluation of amide bioisosteres leading to the discovery of novel and potent thiazolylimidazolidinone inhibitors of SCD1 for the treatment of metabolic diseases.
Journal: Bioorganic & medicinal chemistry letters
Published: October 08, 2013
Last Updated: 09/26/2026